弥漫性大B细胞淋巴瘤治疗进展
Advances in the Treatment of Diffuse Large B-Cell Lymphoma
摘要: 弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma, DLBCL)是非霍奇金淋巴瘤(non-Hodgkin’s lymphoma, NHL)最常见的亚型，包括一组形态学、遗传学和临床上不同的异质性疾病。据估计，全球每年有150,000例新发病例的大B细胞淋巴瘤，患者通常表现为进行性淋巴结肿大、结外病变或两者兼而有之，需要治疗。在过去的二十年里，人们对弥漫性大B细胞淋巴瘤的流行病学、组织学、免疫表型、遗传学特征、临床表现、化疗疗效及预后和生物异质性有了更深入的了解，从而完善了疾病分类并开发了新的治疗方法。在此，我们回顾了DLBCL治疗手段的最新进展，并展望与讨论了DLBCL患者未来的治疗前景。
Abstract: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma (NHL) and comprises a heterogeneous group of morphologically, genetically, and clinically distinct diseases. An estimated 150,000 new cases of large B-cell lymphoma occur globally each year, and patients usually present with progressive lymph node enlargement, extranodal lesions, or both, requiring treatment. Over the past two decades, a better understanding of the epidemiology, his-tology, immunophenotype, genetic features, clinical presentation, chemotherapy efficacy and prog-nosis, and biological heterogeneity of diffuse large B-cell lymphomas has led to refinement of dis-ease classifications and development of new therapeutic approaches. Here, we review the recent advances in the treatment of DLBCL and look forward to and discuss the future prospects for the treatment of patients with DLBCL.
文章引用：伊再提·亚森江, 郭莉. 弥漫性大B细胞淋巴瘤治疗进展[J]. 临床医学进展, 2024, 14(2): 3899-3904. https://doi.org/10.12677/ACM.2024.142542

参考文献

[1] Susanibar-Adaniya, S. and Barta, S.K. (2021) 2021 Update on Diffuse Large B Cell Lymphoma: A Review of Current Data and Potential Applications on Risk Stratification and Management. American Journal of Hematology, 96, 617-629. [Google Scholar] [CrossRef] [PubMed]
[2] Lenz, G., et al. (2008) Stromal Gene Signatures in Large-B-Cell Lym-phomas. The New England Journal of Medicine, 359, 2313-2323. [Google Scholar] [CrossRef] 
[3] Poletto, S., et al. (2022) Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma. Cancer Treatment Reviews, 110, Article ID: 102443. [Google Scholar] [CrossRef] [PubMed]
[4] Gisselbrecht, C., et al. (2010) Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 28, 4184-4190. [Google Scholar] [CrossRef] 
[5] Westin, J.R., et al. (2023) Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. The New England Journal of Medicine, 389, 148-157. [Google Scholar] [CrossRef] 
[6] Nastoupil, L.J. and Bartlett, N.L. (2023) Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 41, 903-913. [Google Scholar] [CrossRef] 
[7] Cheson, B.D., et al. (2014) Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology, 32, 3059-3068. [Google Scholar] [CrossRef] 
[8] Rosenwald, A., et al. (2002) The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. The New England Journal of Medicine, 346, 1937-1947. [Google Scholar] [CrossRef] 
[9] Scott, D.W., et al. (2015) Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Journal of Clinical Oncology, 33, 2848-2856. [Google Scholar] [CrossRef] 
[10] Meyer, P.N., et al. (2011) Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab. Journal of Clinical Oncology, 29, 200-207. [Google Scholar] [CrossRef] 
[11] Muramatsu, M., et al. (2000) Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), A Potential RNA Editing Enzyme. Cell, 102, 553-563. [Google Scholar] [CrossRef] 
[12] Kuppers, R. and Dalla-Favera, R. (2001) Mechanisms of Chromosomal Translocations in B Cell Lymphomas. Oncogene, 20, 5580-5594. [Google Scholar] [CrossRef] [PubMed]
[13] Ramiro, A.R., et al. (2004) AID Is Required for C-Myc/IgH Chro-mosome Translocations in Vivo. Cell, 118, 431-438. [Google Scholar] [CrossRef] [PubMed]
[14] Pasqualucci, L., et al. (2001) Hypermutation of Multiple Pro-to-Oncogenes in B-Cell Diffuse Large-Cell Lymphomas. Nature, 412, 341-346. [Google Scholar] [CrossRef] [PubMed]
[15] International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A Predictive Model for Aggressive Non- Hodgkin’s Lymphoma. The New England Journal of Medicine, 329, 987-994. [Google Scholar] [CrossRef] 
[16] Ruppert, A.S., et al. (2020) International Prognostic Indices in Diffuse Large B-Cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI. Blood, 135, 2041-2048. [Google Scholar] [CrossRef] [PubMed]
[17] Neelapu, S.S., et al. (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England Journal of Medicine, 377, 2531-2544. [Google Scholar] [CrossRef] 
[18] Schuster, S.J., et al. (2017) Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. The New England Journal of Medicine, 377, 2545-2554. [Google Scholar] [CrossRef] 
[19] Schuster, S.J., et al. (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, 380, 45-56. [Google Scholar] [CrossRef] 
[20] Locke, F.L., et al. (2019) Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial. The Lancet Oncology, 20, 31-42. [Google Scholar] [CrossRef] 
[21] Bukhari, A., et al. (2019) Rapid Relapse of Large B-Cell Lymphoma after CD19 Directed CAR-T-Cell Therapy due to CD-19 Antigen Loss. American Journal of Hematology, 94, E273-E275. [Google Scholar] [CrossRef] [PubMed]
[22] Spiegel, J.Y., et al. (2021) CAR T Cells with Dual Targeting of CD19 and CD22 in Adult Patients with Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial. Nature Medicine, 27, 1419-1431. [Google Scholar] [CrossRef] [PubMed]
[23] Suarez, E.R., et al. (2016) Chimeric Antigen Receptor T Cells Secreting Anti-PD-L1 Antibodies More Effectively Regress Renal Cell Carcinoma in a Humanized Mouse Model. Oncotarget, 7, 34341-34355. [Google Scholar] [CrossRef] [PubMed]
[24] Garciaz, S., et al. (2016) Lenalidomide for the Treatment of B-Cell Lymphoma. Expert Opinion on Investigational Drugs, 25, 1103-1116. [Google Scholar] [CrossRef] [PubMed]
[25] Castellino, A., et al. (2018) Lenalidomide Plus R-CHOP21 in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Long-Term Follow-Up Results from a Combined Analysis from Two Phase 2 Trials. Blood Cancer Journal, 8, Article No. 108. [Google Scholar] [CrossRef] [PubMed]
[26] Thieblemont, C., et al. (2017) Lenalidomide Maintenance Com-pared with Placebo in Responding Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 35, 2473-2481. [Google Scholar] [CrossRef] 
[27] Nowakowski, G.S., et al. (2021) ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients with ABC-Type Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 39, 1317-1328. [Google Scholar] [CrossRef] 
[28] Oberic, L., et al. (2021) Subcutaneous Rituximab-MiniCHOP Com-pared with Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. Journal of Clinical Oncology, 39, 1203-1213. [Google Scholar] [CrossRef] 
[29] Nowakowski, G.S., et al. (2021) Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in A Randomized Phase II US In-tergroup Study ECOG-ACRIN E1412. Journal of Clinical Oncology, 39, 1329-1338. [Google Scholar] [CrossRef] 
[30] Hernandez-Ilizaliturri, F.J., et al. (2011) Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like than in Germinal Center B-Cell-Like Phenotype. Cancer, 117, 5058-5066. [Google Scholar] [CrossRef] [PubMed]
[31] Feldman, T., et al. (2014) Addition of Lenalidomide to Rituximab, Ifosfamide, Carboplatin, Etoposide (RICER) in First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma. British Journal of Haematology, 166, 77-83. [Google Scholar] [CrossRef] [PubMed]
[32] Martin, A., et al. (2016) Lenalidomide in Combination with R-ESHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 1b Study from GELTAMO Group. British Journal of Haematology, 173, 245-252. [Google Scholar] [CrossRef] [PubMed]
[33] Nuvvula, S., Dahiya, S. and Patel, S.A. (2022) The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 22, 362-372. [Google Scholar] [CrossRef] [PubMed]
[34] Crump, M., et al. (2014) Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. Journal of Clinical Oncology, 32, 3490-3496. [Google Scholar] [CrossRef] 
[35] Chong, E.A., et al. (2021) Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. The New England Journal of Medicine, 384, 673-674. [Google Scholar] [CrossRef] 
[36] Schuster, S.J., et al. (2021) Long-Term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (JULIET): A Multicentre, Open-Label, Single-Arm, Phase 2 Study. The Lancet Oncology, 22, 1403-1415. [Google Scholar] [CrossRef] 
[37] Locke, F.L., et al. (2022) Axicabtagene Ciloleucel as Se-cond-Line Therapy for Large B-Cell Lymphoma. The New England Journal of Medicine, 386, 640-654. [Google Scholar] [CrossRef] 
[38] Reddy, A., et al. (2017) Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell, 171, 481-494.e15.

为你推荐